141.35
price down icon0.97%   -2.115
after-market アフターアワーズ: 140.82 -0.535 -0.38%
loading
前日終値:
$143.47
開ける:
$142.88
24時間の取引高:
952.56K
Relative Volume:
0.76
時価総額:
$14.37B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
21.73
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+0.97%
1か月 パフォーマンス:
-8.41%
6か月 パフォーマンス:
+6.71%
1年 パフォーマンス:
+2.16%
1日の値動き範囲:
Value
$140.34
$143.02
1週間の範囲:
Value
$140.34
$146.91
52週間の値動き範囲:
Value
$122.14
$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1071)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-10-27
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
141.35 14.07B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.50 60.23B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
39.20 45.71B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
9.255 40.72B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
73.06 29.36B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
532.78 20.39B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Oct 01, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Sep 30, 2026

Neurocrine to present Prader-Willi syndrome research at FPWR event - Investing.com

Sep 30, 2026
pulisher
Sep 30, 2026

Neurocrine to present Prader-Willi syndrome research at FPWR event By Investing.com - Investing.com Nigeria

Sep 30, 2026
pulisher
Sep 30, 2026

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference - PR Newswire

Sep 30, 2026
pulisher
Sep 30, 2026

Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street

Sep 30, 2026
pulisher
Sep 29, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia

Sep 29, 2026
pulisher
Sep 29, 2026

Neurocrine Biosciences selects Ruder Finn as communications AOR - Medical Marketing and Media

Sep 29, 2026
pulisher
Sep 29, 2026

Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - uk.finance.yahoo.com

Sep 29, 2026
pulisher
Sep 29, 2026

Neurocrine Price Target Cut to $214.00/Share From $231.00 by UBS - Moomoo

Sep 29, 2026
pulisher
Sep 29, 2026

UBS cuts Neurocrine Biosciences stock price target to $214 on competition - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

EBITDA margin % of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView

Sep 29, 2026
pulisher
Sep 28, 2026

Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return - Simply Wall Street

Sep 28, 2026
pulisher
Sep 28, 2026

Neurocrine Biosciences names Eiry Roberts as chief medical officer - Investing.com

Sep 28, 2026
pulisher
Sep 28, 2026

Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - marketscreener.com

Sep 28, 2026
pulisher
Sep 28, 2026

Neurocrine names Eiry Roberts chief medical officer - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes - marketscreener.com

Sep 28, 2026
pulisher
Sep 28, 2026

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - PR Newswire

Sep 28, 2026
pulisher
Sep 24, 2026

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - stocktwits.com

Sep 24, 2026
pulisher
Sep 24, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada

Sep 24, 2026
pulisher
Sep 23, 2026

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Eastern Progress

Sep 23, 2026
pulisher
Sep 23, 2026

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance

Sep 23, 2026
pulisher
Sep 22, 2026

Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily

Sep 22, 2026
pulisher
Sep 22, 2026

Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - Eastern Progress

Sep 22, 2026
pulisher
Sep 21, 2026

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com

Sep 21, 2026
pulisher
Sep 21, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 20, 2026

Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - webull.com

Sep 20, 2026
pulisher
Sep 19, 2026

Neurocrine Biosciences stock draws support from strong Q2 figures - AD HOC NEWS

Sep 19, 2026
pulisher
Sep 17, 2026

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story - Yahoo Finance

Sep 17, 2026
pulisher
Sep 16, 2026

NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost - Kalkine Media

Sep 16, 2026
pulisher
Sep 16, 2026

Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com Nigeria

Sep 16, 2026
pulisher
Sep 15, 2026

Neurocrine Biosciences Inc (NBIX) Shares Fall 4.6% -- What GF Sc - GuruFocus

Sep 15, 2026
pulisher
Sep 15, 2026

Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Neurocrine Biosciences (NASDAQ: NBIX) director logs 14,343-share vesting, 7,839 withheld for taxes - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - stocktitan.net

Sep 15, 2026
pulisher
Sep 15, 2026

Neurocrine Biosciences (NBIX) grants HR chief 3,587 shares - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares - stocktitan.net

Sep 15, 2026
pulisher
Sep 15, 2026

CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Is Neurocrine Biosciences (NBIX) Still Undervalued As It Heads Into September Conferences? - Simply Wall Street

Sep 15, 2026
pulisher
Sep 14, 2026

Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews

Sep 14, 2026
pulisher
Sep 12, 2026

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits

Sep 12, 2026
pulisher
Sep 12, 2026

Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily

Sep 12, 2026
pulisher
Sep 10, 2026

Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 10, 2026

Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria

Sep 10, 2026
pulisher
Sep 10, 2026

Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com

Sep 10, 2026
pulisher
Sep 09, 2026

Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan

Sep 09, 2026
pulisher
Sep 09, 2026

Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com

Sep 09, 2026
pulisher
Sep 08, 2026

Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria

Sep 08, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
ABERNETHY MATT
Chief Financial Officer
Sep 14 '26
Sale
157.20
2,311
363,285
42,808
$22.50
price up icon 0.60%
RDY RDY
$12.20
price down icon 0.33%
$17.45
price down icon 0.99%
$19.64
price down icon 0.59%
$532.78
price down icon 1.12%
大文字化:     |  ボリューム (24 時間):